CNS: sex steroids and SERMs.

Area of Science:

• Neuroendocrinology
• Neurosteroidogenesis
• Pharmacology

Background:

• The central nervous system (CNS) is a key target for sex steroid hormones, influencing mood and cognition through genomic and non-genomic pathways.
• Neurosteroids, such as allopregnanolone, are produced in the brain and may be involved in mood and cognitive changes during menopause.
• Selective Estrogen Receptor Modulators (SERMs) offer tissue-specific estrogenic effects, prompting investigation into their neuroendocrine impact.

Purpose of the Study:

• To investigate the impact of SERMs on neuroendocrine pathways and neurosteroid levels in the context of menopausal mood and cognitive changes.
• To evaluate the estrogen-like effects of raloxifene and other SERMs on beta-endorphin and allopregnanolone in animal models and postmenopausal women.

Main Methods:

• Administration of SERMs (LY 117018, EM-652, raloxifene) to ovariectomized rats and postmenopausal women.
• Measurement of beta-endorphin and allopregnanolone levels.
• Assessment of neuroendocrine test responses.

Main Results:

• Raloxifene and other SERMs demonstrated estrogen-like effects on beta-endorphin and allopregnanolone in ovariectomized rats, with anti-estrogenic effects in other models.
• In postmenopausal women, raloxifene administration mimicked estrogen's effects on circulating beta-endorphin and allopregnanolone.
• Raloxifene restored neuroendocrine test responses in postmenopausal women.

Conclusions:

• Positive effects of hormone replacement therapy (HRT) on postmenopausal mood and cognition are linked to neuroendocrine pathway modulation and neurosteroidogenesis.
• Raloxifene's effects on mood and cognition suggest potential for developing improved estrogen replacement therapies with fewer side effects.